Chinese officials will be in Washington on Wednesday to hold consultations with the U.S. ahead of high-level trade talks in October.World Economyread more
President Donald Trump said Monday he's in no rush to respond to a coordinated attack that hit Saudi Arabia's oil industry over the weekend.Marketsread more
The price of oil could go sharply higher, depending on the duration of the disruption at Saudi oil facilities and whether there is a military response.Powering the Futureread more
Energy stocks, one of the worst-performing sectors this year, spiked Monday after an attack on Saudi Arabia's heart of oil production Saturday sent oil prices soaring.Marketsread more
The Saudi-led military coalition battling Yemen's Houthi movement said on Monday that the attack on Saudi oil plants was carried out by Iranian weapons and did not originate...Oilread more
After a series of setbacks on the road to an initial public offering, the parent company of real estate start-up WeWork is delaying the move, sources told CNBC Monday.Technologyread more
"The United States military, with our interagency team, is working with our partners to address this unprecedented attack and defend the international rules-based order that...Politicsread more
Crude oil's spike following attacks on Saudi Arabia's energy supply has experts weighing whether or not the gains will last.ETF Edgeread more
"In the old days, the averages would've plunged on this kind of oil shock. I know because I've lived through a bunch of them, starting in 1973," Jim Cramer says.Mad Money with Jim Cramerread more
Traders in the fed funds futures market on Monday were pricing in a 34% chance that the Fed will stay put on rates.The Fedread more
The meeting comes amid months of stalled trade talks between Washington and New Delhi, resulting in both sides taking retaliatory measures.Asia Politicsread more
(Adds analyst comment, background)
July 10 (Reuters) - GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial, the drugmaker said on Wednesday.
Dovato, a combination of dolutegravir and lamivudine, was approved in the United States in April for newly-diagnosed patients, boosting the British drugmaker's prospects against Gilead Sciences Inc, which currently leads the HIV treatment market.
Liberium analyst Graham Doyle said the study results will add to the data package supporting Dovato as GSK aims to convince doctors that two drug therapies are just as effective as triple therapies.
GSK is betting that a shift to using two drugs rather than three will boost its sales by offering patients a therapy with fewer potentially toxic side effects.
The study evaluated the effectiveness of Dovato in adults with the HIV-1 virus, who switched to the regimen from at least a triple combination containing Gilead's Vemlidy, the British company's HIV drugs division ViiV said.
ViiV also said adults who used Dovato did not develop any resistance to the treatment.
GSK already has a two-drug regimen Juluca on the market, but only for HIV patients that have received prior treatment.
Pfizer Inc and Shionogi & Co Ltd also have small stakes in ViiV, which accounted for about 39% of GSK's group operating profit last year, according to UBS analysts.
The HIV-1 category has the most widespread strains of the virus, which severely affects the body's immune system. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard Orr)